The Boston criteria 2.0 were proposed in 2022 in order to better include leptomeningeal and white matter characteristics into the diagnoses of probable and possible cerebral amyloid angiopathy (CAA) 1. They consist of combined clinical, imaging and pathological parameters, and are based upon the original Boston criteria and modified Boston criteria, which were proposed in 1995 and 2010 respectively 2,3.
It is not to be confused with the Boston criteria for blunt cerebrovascular injury.
Criteria
The criteria are divided into four tiers 1:
-
definite CAA
-
full brain post-mortem examination demonstrating:
spontaneous intracerebral hemorrhage, transient focal neurological episodes, convexity subarachnoid hemorrhage, or cognitive impairment or dementia
severe CAA with vasculopathy
absence of other diagnostic lesion
-
-
probable CAA with supporting pathology
-
clinical data and pathological tissue (evacuated hematoma or cortical biopsy) demonstrating:
presentation with spontaneous intracerebral hemorrhage, transient focal neurological episodes, convexity subarachnoid hemorrhage, or cognitive impairment or dementia
some degree of CAA in specimen
absence of other diagnostic lesion
-
-
probable CAA
pathological confirmation not required
for patients aged 50 years and older
presentation with spontaneous intracerebral hemorrhage, transient focal neurological episodes, or cognitive impairment or dementia
-
MRI criteria:
-
demonstrates either:
at least two of the following strictly lobar hemorrhagic lesions on T2*-weighted MRI, in any combination: intracerebral hemorrhage, cerebral microbleeds, or foci of cortical superficial siderosis (multiple distinct foci are counted as independent hemorrhagic lesions) or convexity subarachnoid hemorrhage (multiple distinct foci are counted as independent hemorrhagic lesions);
ORone lobar hemorrhagic lesion plus one white matter feature (severe perivascular spaces in the centrum semiovale [>20 visible in one hemisphere] or white matter hyperintensities in a multispot pattern [>10 subcortical FLAIR dots bilaterally])
-
in the absence of:
any deep hemorrhagic lesions on T2*-weighted MRI
ANDother cause of hemorrhagic lesions*
hemorrhagic lesion in cerebellum not counted as either lobar or deep hemorrhagic lesion
-
-
possible CAA
pathological confirmation not required
for patients aged 50 years and older
presentation with spontaneous intracerebral hemorrhage, transient focal neurological episodes, or cognitive impairment or dementia
-
MRI criteria:
-
demonstrates either:
one strictly lobar hemorrhagic lesion on T2*-weighted MRI: intracerebral hemorrhage, cerebral microbleeds, or foci of cortical superficial siderosis or convexity subarachnoid hemorrhage;
ORone white matter feature (severe perivascular spaces in the centrum semiovale [>20 visible in one hemisphere] or white matter hyperintensities in a multispot pattern [>10 subcortical FLAIR dots bilaterally])
-
in the absence of:
any deep hemorrhagic lesions on T2*-weighted MRI
ANDother cause of hemorrhagic lesions*
hemorrhagic lesion in cerebellum not counted as either lobar or deep hemorrhagic lesion
-
* "Other cause of hemorrhagic lesions" are: antecedent head trauma, hemorrhagic transformation of an ischemic stroke, arteriovenous malformation, hemorrhagic tumor, warfarin therapy with INR >3, and vasculitis 1.
In its initial publication, the Boston criteria 2.0 for diagnosis of 'probable CAA' was validated against multiple different cohorts, and against patients who had had autopsy it had a sensitivity of 74.5% (95% confidence interval (CI) 65.4% to 82.4%) and specificity of 95% (95% CI 83.1% to 99.4%), which is superior compared to when the modified Boston criteria were applied to the same patient cohorts 1. Notably, when applied to patients who are asymptomatic or only have cognitive impairment, diagnostic accuracy of the Boston criteria 2.0 is much lower, with a diagnosis of 'probable CAA' only having a sensitivity of 28.6% (95% CI 13.2% to 48.7%) and specificity of 65.3% (95% CI 44.3%–82.8%) 4.